Alzheimer’s disease is responsible for up to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually…
Articles by Ana de Barros, PhD
In a recent study published in the journal Computational and Mathematical Methods in Medicine, a team of…
A recent study titled, “ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor…
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company addressing the cognitive, behavioral, and functional components of dementia, recently announced that…
In a recent study published in the Journal of Neuroinflammation, researchers from China were able to identify a…
Type 2 diabetes…
UK-based Dementia Consortium announced that it will grant £500,000 ($790,000) in funding to a collaborative research effort that includes academics from the University of Southampton…
Actinogen Limited, a biotechnology company focused on the treatment of Alzheimer’s Disease and mild cognitive impairment, a transitional stage…
The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by…
Phoenix-based Banner Alzheimer’s Institute (BAI) was recently awarded a joint $10 million research funding grant from the Alzheimer’s…